Identifying Hypoxic Tumors for Improved Cancer Treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to identify hypoxic tumors in patients with bladder and prostate cancer to personalize treatment and improve outcomes. Hypoxic tumors, which have low oxygen levels, often respond poorly to radiotherapy, but can benefit from intensified treatment strategies. The study utilizes gene-expression signature-based biomarkers derived from archived tumor tissue to identify patients with hypoxic tumors, potentially leading to better therapeutic responses. The research is conducted at The Christie NHS Foundation Trust in Manchester, focusing on patients undergoing radiotherapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

This will be tumour site dependent.

Bladder:

* Older than age 18 years.
* Patients having radiotherapy at the Christie NHS Foundation Trust suitable for imaging on an MRI scanner.
* Able to give informed consent.

Cervix:

* Older than age 18 years.
* Patients having radiotherapy at the Christie NHS Foundation Trust suitable for imaging on an MRI scanner.
* Able to give informed consent.

Prostate:

* Older than age 18 years.
* Patients having radiotherapy at the Christie NHS Foundation Trust suitable for imaging on an MRI scanner.
* Able to give informed consent.

Exclusion Criteria:

This will be tumour site dependent

Bladder:

* Any contraindications to MRI identified after MRI safety screening including completion of an MRI Safety Screening Form.
* Unable to tolerate MRI scans.
* Pregnancy.

Cervix:

* Any contraindications to MRI identified after MRI safety screening including completion of an MRI Safety Screening Form.
* Unable to tolerate MRI scans.
* Pregnancy.

Prostate:

* Any contraindications to MRI identified after MRI safety screening including completion of an MRI Safety Screening Form.
* Unable to tolerate MRI scans

Where it's running

• The Christie NHS Foundation Trust
  Manchester, United Kingdom Recruiting

Study contacts

• Principal investigator: Ananya Choudhury, Professor — University of Manchester
• Study coordinator: Rachel Reed, MSc
• Email: rachel.reed@manchester.ac.uk
• Phone: 01619184780

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Virtual exercise program to preserve function and prevent disability during chemotherapy

  This trial tests whether supervised resistance sessions by video plus short home aerobic workouts help adults 18–64 maintain strength and stay active while receiving curative-intent chemotherapy.

  Recruiting at 29 sites Alliance for Clinical Trials in Oncology · Dublin, California and 29 other locations · NCT07059884

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer

  This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.

  Recruiting Niguarda Hospital · Milan, Lombardy · NCT07879820

• BL-M07D1: T-bren vs standard platinum chemo for HER2-expressing metastatic urothelial cancer after anti-PD-(L)1 therapy

  This trial tests whether T-bren can help people with HER2-expressing metastatic urothelial cancer who progressed after anti-PD-(L)1 therapy, compared with standard platinum-based chemotherapy.

  Recruiting at 2 sites Phase 3 SystImmune Inc. · Macon, Georgia and 1 other locations · NCT07869836

• Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer

  This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.

  Recruiting Lithuanian University of Health Sciences · Kaunas · NCT07863986

• Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer

  This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.

  Recruiting at 8 sites Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic · Benidorm, Alicante and 9 other locations · NCT07860528

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.